Article

IVI Research Brief Explores Implications of "Value of Hope"

A research brief from the Innovation and Value Initiative (IVI) took a look at how accounting for patients’ attitudes towards risks in treatment outcomes affects value.

A research brief from the Innovation and Value Initiative (IVI) took a look at how accounting for patients’ attitudes towards risks in treatment outcomes affects value. Focusing on non-small cell lung cancer (NSCLC), the brief used the IVI-NSCLC model, an open-source simulation model that assesses the costs, benefits, and risks of sequences of treatment for EGFR-mutated disease. The model also includes an experimental module for calculating the value of hope, which has been suggested as one of the elements to augment conventional cost-effectiveness analysis.

Costs and outcomes for 2 possible treatment sequences were determined and the value of hope was added to the quality-adjusted life years (QALYs) by estimating the QALYs a patient would need to obtain to be indifferent toward the 2 sequences of treatment.

Read the full research brief.

Related Videos
Andrew Kuykendall, MD, Moffitt Cancer Center
Joshua Kaufman, MD, CDPHP
Cathy Eng, MD, FACP, FASCO
Andrew Kuykendall, MD, Moffitt Cancer Center
Frederick L. Locke, MD, Moffitt Cancer Center and Research Institute
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Douglas Flora, MD, FACCC
rachel rohaidy
Douglas Flora, MD, FACCC
Fred Locke, MD, Moffitt Cancer Center and Research Institute
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo